Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kobayashi Pharmaceutical CoKBYPF -2.71%80 EV-to-EBIT is 83.00 as of Aug. 13, 2026, which is 289% above its 10-year median of 21.35. GuruFocus rates KBYPF with a GF Score™ of 80/100 and a GF Value™ of $26.62. The stock has 6 warning signs investors should review. Among 1,557 Consumer Packaged Goods companies, Kobayashi Pharmaceutical Co ranks worse than 95.38% on this metric.
Kobayashi Pharmaceutical Co (OTCPK:KBYPF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Kobayashi Pharmaceutical Co's Enterprise Value for the quarter that ended in Jun. 2026 was $2,179 Mil.
Kobayashi Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kobayashi Pharmaceutical Co EV-to-EBIT Related Terms
Kobayashi Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Kobayashi Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kobayashi Pharmaceutical Co EV-to-EBIT vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Kobayashi Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Kobayashi Pharmaceutical Co's EV-to-EBIT falls into.
Kobayashi Pharmaceutical Co's current Enterprise Value is $2,240 Mil.
Kobayashi Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kobayashi Pharmaceutical Co (KBYPF) has a EV-to-EBIT of 83.00 as of Aug. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kobayashi Pharmaceutical Co and its competitors. This is 289% above median its historical median of 21.35. Over the past decade, Kobayashi Pharmaceutical Co's EV-to-EBIT has ranged from 10.63 to 288.08. According to the industry distribution chart, Kobayashi Pharmaceutical Co ranks #1485 out of 1557 companies in the Consumer Packaged Goods industry, placing it in the top 95.4%.
Is Kobayashi Pharmaceutical Co's EV-to-EBIT too high?
Kobayashi Pharmaceutical Co's current EV-to-EBIT of 83.00 is 289% above median its 10-year median of 21.35. Over the past 10 years, this metric has ranged from a low of 10.63 to a high of 288.08. The Consumer Packaged Goods industry median EV-to-EBIT is 12.11. Kobayashi Pharmaceutical Co's value of 83.00 is 585.4% above this industry median. Based on the distribution chart, Kobayashi Pharmaceutical Co ranks #1485 out of 1557 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Kobayashi Pharmaceutical Co has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Kobayashi Pharmaceutical Co's EV-to-EBIT compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Kobayashi Pharmaceutical Co ranks #1485 out of 1557 companies for EV-to-EBIT. This places Kobayashi Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBIT is 12.11. Kobayashi Pharmaceutical Co's value of 83.00 is 585.4% above this benchmark. Historically, Kobayashi Pharmaceutical Co's own EV-to-EBIT has ranged from 10.63 to 288.08 over the past decade. While the company's 10-year median is 21.35 vs. the industry median of 12.11, Kobayashi Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Consumer Packaged Goods company?
The median EV-to-EBIT among Consumer Packaged Goods companies is 12.11, based on 1,557 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kobayashi Pharmaceutical Co's current EV-to-EBIT of 83.00 is 585.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kobayashi Pharmaceutical Co and its competitors. For the Consumer Packaged Goods industry, the median EV-to-EBIT is 12.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kobayashi Pharmaceutical Co's current EV-to-EBIT is 83.00, which is 289% above median its own 10-year median of 21.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kobayashi Pharmaceutical Co stock overvalued right now?
Kobayashi Pharmaceutical Co (KBYPF) has a current EV-to-EBIT of 83.00. The stock's GF Value™ is $26.62, compared to a current price of $34.05 — trading 27.9% above its estimated fair value. The current EV-to-EBIT is 83.00, which is 289% above median its 10-year median of 21.35 and 585.4% above the Consumer Packaged Goods industry median of 12.11. Kobayashi Pharmaceutical Co's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Kobayashi Pharmaceutical Co (KBYPF), the current EV-to-EBIT is 83.00 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kobayashi Pharmaceutical Co (KBYPF) Overvalued in 2026?
Based on GuruFocus' analysis, Kobayashi Pharmaceutical Co stock appears to be overvalued.
The current stock price of $34.05 is trading 27.9% above its estimated GF Value™ of $26.62.
Key valuation signals for KBYPF:
EV-to-EBIT: 83.00 (289% above median its 10-year median of 21.35)
GF Value™: $26.62 vs. price of $34.05 (27.9% above fair value)
Industry Position: 585.4% above the Consumer Packaged Goods median (#1485 of 1557)
No single metric tells the full story. See the KBYPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kobayashi Pharmaceutical Co Ltd is engaged in the manufacture and sale of healthcare products, daily necessities, and body warmers. The company operates through two reportable segments: Domestic Business and International Business, which handle production and sales activities in Japan and overseas, respectively. The company's product portfolio includes disposable body warmers, cooling gel sheets, OTC pharmaceuticals, oral hygiene products, air fresheners, eyeglass wipes, and deodorizing/household sundries.
80GF Score
Get the complete analysis for KBYPF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KBYPF has been successfully added to your 
